Published in Blood Weekly, August 21st, 2003
In a recent study from Italy, scientists "aimed to ascertain whether extracorporeal photochemotherapy (ECP) is an effective treatment for pediatric patients with refractory graft-versus-host disease (GVHD)."
"From January 1992 to December 2000, 77 children (median age 8.6 years) with either acute (n=33) or chronic (n=44) GVHD, resistant to conventional immunosuppressive therapy, were treated with ECP in four Italian pediatric hospitals," according to C. Messina and coauthors at the University of Padua.
"After ECP, acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.